Cancer Clinical Research Unit

Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC). - Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade 2 peripheral neuropathy. - History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing. - Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease. - Uncontrolled, or significant cardiovascular disease or cerebrovascular disease. - Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids. - Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed. - Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention. - Known active central nervous system metastases and/or carcinomatous meningitis. - Active infection requiring systemic therapy. - History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. - HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. - Concurrent active HBV and HCV infection. - History of allogeneic tissue/solid organ transplant. - Participants who have not adequately recovered from major surgery or have ongoing surgical complications.